News | Cath Lab | March 21, 2018

American College of Cardiology Expands Patient Navigator Program

Patient-centered program to focus on reducing myocardial infarction readmissions nationally

American College of Cardiology Expands Patient Navigator Program

March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help improve care and lower readmission rates for myocardial infarction (MI) patients as part of the American College of Cardiology’s expanded Patient Navigator Program: Focus MI Quality Campaign.

With support from founding sponsor AstraZeneca, the expanded program will provide hospitals participating in the ACC’s ACTION Registry the opportunity to transform care by sharing successful strategies, mentorship, and specialized tools and resources. In addition, 15 of the original 35 hospitals from the first phase of the Patient Navigator Program will focus on identifying best practices for improving patient care and readmissions, including 30 and 90 days follow-up post-hospital discharge – an increasing area of focus for proposed payment and reimbursement models.

“Since the original Patient Navigator Program launched, hospitals and cardiovascular care team members have led the way in developing effective ways to help manage patients’ heart health after they leave the hospital,” said ACC President Mary Norine Walsh, M.D., FACC. “The Patient Navigator Program: Focus MI aims to build on what we have learned to help hospitals across the country reduce readmission rates while improving patients’ long-term outcomes.”

A total of 35 U.S. hospitals participated in the initial Patient Navigator Program, which launched in 2013 and focused on reducing 30-day hospital readmissions for MI and heart failure patients. Hospitals participating in the program reported increases in the number of MI patients assessed for risk of readmissions and greater understanding among MI and heart failure patients about their medications. In addition, they were able to reach both groups of patients with education and community resources aimed at ensuring smoother patient transitions from hospital to home. Results were presented in greater detail at ACC’s 67th Annual Scientific Session, March 10-12 in Orlando, Fla.

Hospitals that enroll in the Patient Navigator Program: Focus MI access evidence-based toolkits, self-assessment tools, a learning community of national experts and peer colleagues, and an ACTION Registry dashboard specifically designed to track Patient Navigator Program: Focus MI metrics. The select 15 Diplomat Hospitals, focus on reducing 90-day readmissions for MI patients and provide mentorship for wider adoption of the program across other institutions.

For more information: www.acc.org

 

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init